Gabather (GABA.ST) Stock Analysis & AI Equity Report
Gabather (GABA.ST) overview
Gabather (GABA.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Gabather reported revenue of SEK 0m and operating profit of SEK -7.8m; the year-end share price was 0.40 SEK and market capitalisation was SEK 8.3m. Gabather is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Gabather's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Gabather
Gabather AB is a clinical-stage pharmaceutical company developing novel drug candidates for central nervous system disorders. Its work centers on GABA_A receptor modulators designed to restore brain balance and improve cognition. The company’s pipeline includes GT-002 and other proprietary compounds, supported by patent-protected research aimed at neuropsychiatric conditions.
Generate the Gabather report
Gabather is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Gabather and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.